Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02409121 : A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
PhaseN/A
AgesMin: 10 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Participants will be recruited by BMT RN Coordinators and physicians prior to patient
admission to the Pediatric BMT Unit. Caregiver (age 18 years or older) of any patient
eligible to undergo autologous or allogeneic BMT and any patient (age 10 years or
older) eligible to undergo autologous or allogeneic BMT will be recruited during the
"Pre-Transplant Work-up" stage in the outpatient setting.

- CAREGIVER PARTICIPANTS: Caregiver (age 18 years or older) of a patient who will be
hospitalized to undergo first-time autologous (self) or allogeneic (alternative
donor) BMT in the University of Michigan Mott Children's Hospital Pediatric BMT Unit.
The age range of patients typically transplanted in the Pediatric BMT unit is 0-25
years. Caregivers with children (patients) who are younger than 10 years of age may
be eligible to participate even though their children are too young to assent or
participate themselves.

- PATIENT PARTICIPANTS: Patient (age 10 years or older) who will be hospitalized to
undergo first-time autologous or allogeneic BMT will be given the opportunity to
assent/consent and participate in the study. With his/her permission, the patient
will also be provided with their own iPad® BMT Roadmap information system to use.
Qualitative interviews will be conducted in patients (age 10 years or older) with
their assent/consent. However, patients (age 10-17.9 years) will not be asked to
complete surveys, because they have not been validated in this age group. Patients
(18 years or older) will be asked to complete surveys. The upper age limit is
typically 25 years on the Pediatric BMT Unit. This limit will be determined by only
those patients undergoing transplant in the Pediatric BMT Unit.

- Ability to speak and read proficiently in English (the study's instruments have not
been translated and validated in languages other than English)

- Willing and able to provide informed consent

- Willing to comply with study procedures and reporting requirements.

Exclusion Criteria:

- Not willing and able to provide informed consent.

- Not willing to comply with study procedures and reporting requirements.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02409121      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740